Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | RGS4 | P49798 | 3/20 | 0.37 |
| ▸ | RGS8 | P57771 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058512 | 0.90 | ADORA2A (0.38) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4769165 | 0.89 | PDE4A (0.39) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL8174835 | 0.88 | NCOA1 (0.43) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL17528547 | 0.86 | SMN1; SMN2 (0.36) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4767319 | 0.85 | ALDH1A1 (0.42) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4767903 | 0.81 | RGS4 (0.46) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL8176996 | 0.80 | RGS4 (0.36) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4772714 | 0.80 | ADORA2B (0.39) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL4766301 | 0.80 | RGS4 (0.47) | ADORA2ATNFNCOA1NCOA3RGS4 | |
| SCHEMBL4762458 | 0.79 | PDE1A (0.44) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440983-B2 | Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | PDE4A 182/4885ADORA2A 2/4885PDE4B 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.